{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:31Z","timestamp":1792979911381,"version":"4.5.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is an uncommon but clinically significant event, with isolated CNS involvement occurring in a minority of cases and often eluding standard surveillance protocols. We report the case of a 60-year-old man with biallelic CEBPA-mutated AML and complex cytogenetics who achieved two complete remissions over four years before developing isolated leptomeningeal relapse involving the cauda equina. Despite a favorable molecular profile, CSF analysis revealed more than 3,000 WBCs with 97% blasts in the absence of marrow disease. The patient was treated with intrathecal methotrexate, cytarabine, and hydrocortisone, and later transitioned to an Ommaya reservoir. His response was complicated by persistent neurologic deficits and treatment-related neurotoxicity, culminating in functional decline, disease progression in the CNS, and death under hospice care. This case underscores the diagnostic and therapeutic challenges of isolated CNS recurrence in AML, including limited intrathecal drug delivery to nerve roots, the lack of CSF molecular profiling, and the potential for clonal evolution. Given the poor prognosis and therapeutic resistance associated with such cases, our findings support the consideration of CSF surveillance and combined systemic-intrathecal therapy in high-risk patients, particularly those with monocytic subtypes, elevated LDH, or complex cytogenetics.<\/jats:p>","DOI":"10.3389\/fonc.2025.1667681","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:11Z","timestamp":1760933651000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges"],"prefix":"10.3389","volume":"15","author":[{"given":"Colin","family":"Burns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Emanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100910","article-title":"Neurologic complications of acute myeloid leukemia: Diagnostic approach and therapeutic modalities","volume":"53","author":"Siegal","year":"2022","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.46989\/001c.131722","article-title":"Therapeutics of acute myeloid leukemia with central nervous system involvement","volume":"7","author":"Su\u00e1rez","year":"2025","journal-title":"Clin Hematol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004999","article-title":"CNS involvement in AML at diagnosis is rare and does not affect response or survival: Data from 11 ECOG-ACRIN trials","volume":"5","author":"Ganzel","year":"2021","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-79-4-541","article-title":"Neurological complications of acute leukemia in adults: Changing rate","volume":"79","author":"Dawson","year":"1973","journal-title":"Ann Internal Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197403)33:3<863::AID-CNCR2820330336>3.0.CO;2-1","article-title":"The incidence of central nervous system leukemia in adults with acute leukemia","volume":"33","author":"Wolk","year":"1974","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26253","article-title":"Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease","volume":"118","author":"Shihadeh","year":"2011","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01032-5","article-title":"Central nervous system prophylaxis and treatment in acute leukemias","volume":"23","author":"Wu","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1179\/1607845413Y.0000000117","article-title":"Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia","volume":"19","author":"Zheng","year":"2013","journal-title":"Hematology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2103-127","article-title":"Central nervous system involvement in patients with acute myeloid leukemia","volume":"51","author":"Ya\u015far","year":"2021","journal-title":"Turkish J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.042960","article-title":"Central nervous system involvement at first relapse in patients with acute myeloid leukemia","volume":"96","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2011","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.02.006","article-title":"Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome","volume":"55","author":"Del Principe","year":"2018","journal-title":"Semin Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01220-4","article-title":"Central nervous system involvement in adults with acute leukemia: Diagnosis, prevention, and management","volume":"24","author":"Paul","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.953148","article-title":"Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia","volume":"56","author":"Rozovski","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"B14","article-title":"The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement","volume":"82","author":"Castagnola","year":"1997","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268565","article-title":"Methotrexate-related central neurotoxicity: Clinical characteristics, risk factors and genome wide association study in children treated for acute lymphoblastic leukemia","volume":"107","author":"Mateos","year":"2022","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20280","article-title":"The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia","volume":"100","author":"Sanders","year":"2004","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.4236.4236","article-title":"The incidence of central nervous system involvement in AML: A SAL-Tor Vergata analysis","volume":"118","author":"Alakel","year":"2011","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7482","article-title":"Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia","volume":"23","author":"Johnston","year":"2005","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1727-z","article-title":"Myelopathy following intrathecal chemotherapy in adults: A single institution experience","volume":"122","author":"Cachia","year":"2015","journal-title":"J Neuro-Oncology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1667681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:12Z","timestamp":1760933652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1667681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1667681"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1667681","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1667681"}}